|
Bicycle Therapeutics Plc (BCYC) |
|
Bicycle Therapeutics Plc
BCYC's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bicycle Therapeutics Plc's sales fell
by -30.44 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 929
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Bicycle Therapeutics Plc net loss increased from $-49 millions, to $-52 millions in IV. Quarter 2024,
• More on BCYC's Growth
|
|
Bicycle Therapeutics Plc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.43 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 14.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
• More on BCYC's Valuation
|
|
|
|
|
Bicycle Therapeutics Plc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.43 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 14.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
Bicycle Therapeutics Plc Price to Book Ratio is at 0.64 lower than Industry Avg. of 78.87. and higher than S&P 500 Avg. of 0.01
• More on BCYC's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com